Phaco-ECP vs Phaco Alone in Primary Angle Closure
Launched by KING KHALED EYE SPECIALIST HOSPITAL · Sep 18, 2020
Trial Information
Current as of April 27, 2025
Unknown status
Keywords
ClinConnect Summary
The purpose of our current randomized clinical trial is to compare phacoemulsification with endoscopic cyclophotocoagulation (PHE) versus phacoemulsification alone (PHA) in patients with either primary angle closure (PAC) or primary angle closure glaucoma (PACG) presenting with cataract or a clear lens.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age is above 40 years old.
- • 2. A diagnosis of either PAC or PACG. PAC will be defined as the presence of irido-trabecular contact on gonioscopy, either appositional or in the presence of peripheral anterior synechiae (PAS), without indentation (or prior documentation before a LPI has been performed) without any evidence of glaucomatous optic neuropathy. PACG will be defined as PAC along with an evidence of glaucomatous optic neuropathy. An optic neuropathy secondary to glaucoma will be defined as evidence of structural and functional damage suggestive of glaucoma as demonstrated by clinical examination, optical coherence tomography, and visual field testing.
- • 3. IOP measurement that is more than 21 mmHg (not exceeding 35 mmHg) without the use of glaucoma medications or less than 21 mmHg with medications.
- • 4. Patient is able to give an informed consent and tolerate a period of medication washout.
- Exclusion Criteria:
- • 1. Previous intraocular surgery (including CPC). Glaucoma laser procedures are allowed (e.g. LPI, iridoplasty, and laser trabeculoplasty).
- • 2. Previous ocular trauma.
- • 3. A central corneal thickness that does not lie between 500 and 600 microns.
- • 4. A diagnosis of nanophthalmos (defined as an axial length that is less than 20 mm).
- • 5. Presence of pseudoexfoliation.
- • 6. Presence of secondary causes of angle closure such as neovascular glaucoma and uveitic glaucoma.
- • 7. Presence of diabetic retinopathy (active PDR or active DME) or agerelated macular degeneration. PHEPHA Protocol Version 2 September 3, 2020
- • 8. Advanced glaucoma as defined by the Glaucoma Severity Staging System12 (mean deviation worse than -12.01 dB and at least one of the following: 1. On pattern deviation plot, greater than or equal to 50% but fewer than 75% of points depressed below the 5% level and greater than or equal to 25% but fewer than 50% of points depressed below 1% level 2. Any point within central 5 degrees with sensitivity \< 0db 3. Both hemifields containing a point(s) with sensitivity \< 15 dB within 5 degrees of fixation).
- • 9. Any ocular or systemic condition that is presumed to prevent reliable clinical examination and/or visual field testing.
- • 10. Pregnancy.
- • 11. Inability to attend postoperative follow ups for a period of 12 months after surgery.
About King Khaled Eye Specialist Hospital
King Khaled Eye Specialist Hospital is a premier healthcare institution dedicated to advancing the field of ophthalmology through innovative research and clinical trials. Renowned for its state-of-the-art facilities and expert team of specialists, the hospital focuses on delivering high-quality eye care while fostering a collaborative environment for scientific inquiry. Committed to improving patient outcomes, King Khaled Eye Specialist Hospital actively participates in clinical research that explores new treatments and technologies, aiming to enhance the understanding and management of ocular diseases. Through its rigorous adherence to ethical standards and regulatory compliance, the hospital plays a pivotal role in shaping the future of eye health both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Riyadh, , Saudi Arabia
Patients applied
Trial Officials
Adi Al Owaifeer, MBBS
Principal Investigator
King Khaled Eye Specialist Hospital
Ibrahim Alobaida, MD
Principal Investigator
King Khaled Eye Specialist Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials